A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency

  1. Baptiste Fouquet
  2. Patrycja Pawlikowska
  3. Sandrine Caburet
  4. Celine Guigon
  5. Marika Mäkinen
  6. Laura Tanner
  7. Marja Hietala
  8. Kaja Urbanska
  9. Laura Bellutti
  10. Bérangère Legois
  11. Bettina Bessieres
  12. Alain Gougeon
  13. Alexandra Benachi
  14. Gabriel Livera
  15. Filippo Rosselli
  16. Reiner A Veitia
  17. Micheline Misrahi  Is a corresponding author
  1. Faculté de médecine Paris Sud, France
  2. Université Paris Sud, France
  3. Université Paris Diderot, France
  4. Turku University Hospital, Finland
  5. Hôpital Necker-enfants malades, APHP, France
  6. Faculté de Médecine Laennec, France

Abstract

Primary Ovarian Insufficiency (POI) affects ~1% of women under forty. Exome sequencing of two Finnish sisters with non-syndromic POI revealed a homozygous mutation in FANCM, leading to a truncated protein (p.Gln1701*). FANCM is a DNA-damage response gene whose heterozygous mutations predispose to breast cancer. Compared to the mother's cells, the patients' lymphocytes displayed higher levels of basal and mitomycin C (MMC)-induced chromosomal abnormalities. Their lymphoblasts were hypersensitive to MMC and MMC-induced monoubiquitination of FANCD2 was impaired. Genetic complementation of patient's cells with wild-type FANCM improved their resistance to MMC re-establishing FANCD2 monoubiquitinationFANCM was more strongly expressed in human fetal germ cells than in somatic cells. FANCM protein was preferentially expressed along the chromosomes in pachytene cells, which undergo meiotic recombination. This mutation may provoke meiotic defects leading to a depleted follicular stock, as in Fancm-/- mice. Our findings document the first Mendelian phenotype due to a biallelic FANCM mutation.

Article and author information

Author details

  1. Baptiste Fouquet

    Hopital Bicetre, Faculté de médecine Paris Sud, Le Kremlin Bicetre, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Patrycja Pawlikowska

    CNRS UMR8200, Université Paris Sud, Villejuif, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Sandrine Caburet

    Molecular Oncology and Ovarian Pathologies, Institut Jacques Monod, Université Paris Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7404-8213
  4. Celine Guigon

    CNRS, UMR 8251, INSERM, U1133, Université Paris Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Marika Mäkinen

    Department of Clinical Genetics, Turku University Hospital, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.
  6. Laura Tanner

    Department of Clinical Genetics, Turku University Hospital, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.
  7. Marja Hietala

    Department of Clinical Genetics, Turku University Hospital, Turku, Finland
    Competing interests
    The authors declare that no competing interests exist.
  8. Kaja Urbanska

    CNRS UMR8200, Université Paris Sud, Villejuif, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Laura Bellutti

    UMR967 INSERM, CEA/DRF/iRCM/SCSR/LDG, Université Paris Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Bérangère Legois

    Institut Jacques Monod, Université Paris Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Bettina Bessieres

    Department of Histology, Embryology and Cytogenetics, Hôpital Necker-enfants malades, APHP, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Alain Gougeon

    UMR Inserm 1052, CNRS 5286, Faculté de Médecine Laennec, Lyon, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Alexandra Benachi

    Department of Obstetrics and Gynaecology, Université Paris Sud, Clamart, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Gabriel Livera

    UMR967 INSERM, CEA/DRF/iRCM/SCSR/LDG, Université Paris Diderot, Fontenay aux Roses, France
    Competing interests
    The authors declare that no competing interests exist.
  15. Filippo Rosselli

    CNRS UMR8200, Université Paris Sud, Villejuif, France
    Competing interests
    The authors declare that no competing interests exist.
  16. Reiner A Veitia

    Institut Jacques Monod, Université Paris Diderot, Paris, France
    Competing interests
    The authors declare that no competing interests exist.
  17. Micheline Misrahi

    Hopital Bicetre, Faculté de médecine Paris Sud, Le Kremlin Bicetre, France
    For correspondence
    Micheline.misrahi@aphp.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5379-8859

Funding

Fondation pour la Recherche Médicale (DEQ20150331757)

  • Baptiste Fouquet
  • Sandrine Caburet
  • Reiner A Veitia
  • Micheline Misrahi

Ligue Contre le Cancer

  • Patrycja Pawlikowska
  • Filippo Rosselli

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: The study was approved by all the institutions involved. All participants gave informed consent for the study and the study was approved by the agence de Biomedecine (reference number PFS12-002).

Copyright

© 2017, Fouquet et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,524
    views
  • 414
    downloads
  • 69
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Baptiste Fouquet
  2. Patrycja Pawlikowska
  3. Sandrine Caburet
  4. Celine Guigon
  5. Marika Mäkinen
  6. Laura Tanner
  7. Marja Hietala
  8. Kaja Urbanska
  9. Laura Bellutti
  10. Bérangère Legois
  11. Bettina Bessieres
  12. Alain Gougeon
  13. Alexandra Benachi
  14. Gabriel Livera
  15. Filippo Rosselli
  16. Reiner A Veitia
  17. Micheline Misrahi
(2017)
A homozygous FANCM mutation underlies a familial case of non-syndromic primary ovarian insufficiency
eLife 6:e30490.
https://doi.org/10.7554/eLife.30490

Share this article

https://doi.org/10.7554/eLife.30490

Further reading

    1. Immunology and Inflammation
    2. Medicine
    Ole Bæk, Tik Muk ... Duc Ninh Nguyen
    Research Article

    Preterm infants are susceptible to neonatal sepsis, a syndrome of pro-inflammatory activity, organ damage, and altered metabolism following infection. Given the unique metabolic challenges and poor glucose regulatory capacity of preterm infants, their glucose intake during infection may have a high impact on the degree of metabolism dysregulation and organ damage. Using a preterm pig model of neonatal sepsis, we previously showed that a drastic restriction in glucose supply during infection protects against sepsis via suppression of glycolysis-induced inflammation, but results in severe hypoglycemia. Now we explored clinically relevant options for reducing glucose intake to decrease sepsis risk, without causing hypoglycemia and further explore the involvement of the liver in these protective effects. We found that a reduced glucose regime during infection increased survival via reduced pro-inflammatory response, while maintaining normoglycemia. Mechanistically, this intervention enhanced hepatic oxidative phosphorylation and possibly gluconeogenesis, and dampened both circulating and hepatic inflammation. However, switching from a high to a reduced glucose supply after the debut of clinical symptoms did not prevent sepsis, suggesting metabolic conditions at the start of infection are key in driving the outcome. Finally, an early therapy with purified human inter-alpha inhibitor protein, a liver-derived anti-inflammatory protein, partially reversed the effects of low parenteral glucose provision, likely by inhibiting neutrophil functions that mediate pathogen clearance. Our findings suggest a clinically relevant regime of reduced glucose supply for infected preterm infants could prevent or delay the development of sepsis in vulnerable neonates.

    1. Medicine
    2. Microbiology and Infectious Disease
    Kavidha Reddy, Guinevere Q Lee ... Thumbi Ndung'u
    Research Article

    Persisting HIV reservoir viruses in resting CD4 T cells and other cellular subsets are a barrier to cure efforts. Early antiretroviral therapy (ART) enables post-treatment viral control in some cases, but mechanisms remain unclear. We hypothesised that ART initiated before peak viremia impacts HIV-1 subtype C reservoirs. We studied 35 women at high risk of infection from Durban, South Africa, identified with hyperacute HIV by twice-weekly HIV-RNA testing. Participants included 11 starting ART at a median of 456 (297–1203) days post-onset of viremia (DPOV) and 24 at 1 (1–3) DPOV. Peripheral blood mononuclear cells (PBMCs) were used to measured total HIV-1 DNA by droplet digital PCR (ddPCR) and sequence viral reservoir genomes by full-length proviral sequencing (FLIP-seq). ART during hyperacute infection blunted peak viremia (p<0.0001), but contemporaneous total HIV-1 DNA did not differ (p=0.104). Over 1 year, a decline of total HIV-1 DNA was observed in early treated persons (p=0.0004), but not late treated. Among 697 viral genome sequences, the proviral genetic landscape differed between untreated, late treated, and early treated groups. Intact genomes after 1 year were higher in untreated (31%) versus late treated (14%) and early treated (0%). Treatment in both late and early infection caused more rapid decay of intact (13% and 51% per month) versus defective (2% and 35%) viral genomes. However, intact genomes persisted 1 year post chronic treatment but were undetectable with early ART. Early ART also reduced phylogenetic diversity of intact genomes and limited cytotoxic T lymphocyte immune escape variants in the reservoir. Overall, ART initiated in hyperacute HIV-1 subtype C infection did not impact reservoir seeding but was associated with rapid intact viral genome decay, reduced genetic complexity, and limited immune escape, which may accelerate reservoir clearance in combination with other interventional strategies.